Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease DOI Creative Commons
Hayam A Alrasheed, Mostafa M. Bahaa,

Thanaa A. El‐Masry

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: May 2, 2025

Background Parkinson’s disease (PD) is caused by the progressive loss of dopaminergic neurons in substantia nigra. Neuroinflammation considered a key factor contributing to pathophysiology PD. Current gold-standard therapies for PD provide only symptomatic relief without slowing progression, highlighting need develop new disease-modifying treatments. Metformin has been demonstrated exert neuroprotective role several neurodegenerative disorders including Aim This study aimed clarify metformin as adjuvant therapy patients with Methods Sixty were divided into 2 groups (n = 30). Patients group 1 received levodopa/carbidopa (250/25 mg) three times daily 3 months plus placebo (Control group), while those and 500 mg two (Metformin group). assessed via Unified Disease Rating Scale (UPDRS). The serum concentrations toll like receptor 4 (TLR-4), α-synuclein, brain derived neurotropic (BDNF), high mobility box (HMGB-1) measured before after treatment. Primary outcome improvement UPDRS from baseline months. Secondary Change level biological markers. Results control did not show significant difference when compared their value Wilcoxon test ( P > 0.05), meanwhile showed treatment < 0.05). There no differences between 0.05) Man Whitney test. However, decrease TLR-4, HMGB-1, α-synuclein along statistically increase BDNF its group. any changes all markers baseline. Conclusion While scores observed groups, trends biomarker suggest potential impact adjunctive use on underlying Further studies are needed assess effects motor symptoms over longer duration. Clinical Trial Registration identifier NCT05781711.

Language: Английский

Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study DOI

Mohannad O Khrieba,

Sahar K. Hegazy,

Wessam Fathi Mohammed

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 156, P. 114689 - 114689

Published: April 19, 2025

Language: Английский

Citations

0
Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease DOI Creative Commons
Hayam A Alrasheed, Mostafa M. Bahaa,

Thanaa A. El‐Masry

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: May 2, 2025

Background Parkinson’s disease (PD) is caused by the progressive loss of dopaminergic neurons in substantia nigra. Neuroinflammation considered a key factor contributing to pathophysiology PD. Current gold-standard therapies for PD provide only symptomatic relief without slowing progression, highlighting need develop new disease-modifying treatments. Metformin has been demonstrated exert neuroprotective role several neurodegenerative disorders including Aim This study aimed clarify metformin as adjuvant therapy patients with Methods Sixty were divided into 2 groups (n = 30). Patients group 1 received levodopa/carbidopa (250/25 mg) three times daily 3 months plus placebo (Control group), while those and 500 mg two (Metformin group). assessed via Unified Disease Rating Scale (UPDRS). The serum concentrations toll like receptor 4 (TLR-4), α-synuclein, brain derived neurotropic (BDNF), high mobility box (HMGB-1) measured before after treatment. Primary outcome improvement UPDRS from baseline months. Secondary Change level biological markers. Results control did not show significant difference when compared their value Wilcoxon test ( P > 0.05), meanwhile showed treatment < 0.05). There no differences between 0.05) Man Whitney test. However, decrease TLR-4, HMGB-1, α-synuclein along statistically increase BDNF its group. any changes all markers baseline. Conclusion While scores observed groups, trends biomarker suggest potential impact adjunctive use on underlying Further studies are needed assess effects motor symptoms over longer duration. Clinical Trial Registration identifier NCT05781711.

Language: Английский

Citations

0